More than 250 participants have been enrolled in a trial evaluating Gilead’s experimental antiviral pill obeldesivir as a post-exposure prophylaxis for the Bundibugyo virus in the Democratic Republic of the Congo. The study addresses an ongoing outbreak in Ituri province that has recorded at least 8,300 confirmed cases and 4,000 deaths since mid-May.
Clinical Trial Details and Drug Mechanism
The trial is testing whether obeldesivir can stop people from contracting Ebola when administered soon after suspected contact with the virus. This approach is known as post-exposure prophylaxis, or PEP. Coordinated by the medical non-profit body Alima, the study aims to recruit nearly 1,000 adults and children over the age of 12 who have encountered a confirmed case within the previous five days and currently show no symptoms.
Half of the participants receive a placebo, while researchers monitor everyone in person daily for 21 days, followed by a final phone check at 42 days, as noted by Dr. Godefroid Basara. Alima research coordinator Dr. Guilavogui Jean Paul Yassa stated that the oral antiviral functions differently from vaccines, which require days or weeks to generate protection, and differs from curative treatments intended for symptomatic patients.
Outbreak Epicenter and Participant Experiences
The research is stationed at a health center in Ituri province, the epicenter of an outbreak that has spread across seven provinces. Participants include high-risk individuals such as healthcare workers and relatives of patients. One trial participant, identified under anonymity as EBO-PEP, enrolled in August after her husband tested positive, noting that no members of her household had developed symptoms so far. Another participant reported that two family members contracted the disease and one died, prompting them to take precautions.
Investigating physician Dr. Jacques Zawadi noted that while most participants willingly join the study, logistical hurdles remain significant for individuals living far from the center. Emotional distress from family bereavements frequently disrupts participant retention, according to trial staff.
Institutional Coordination and Next Steps
The trial partnerships involve Alima alongside the National Institute of Biomedical Research of the Congo and the French institute ANRS Emerging Infectious Diseases. If participants develop symptoms during the monitoring window, they immediately receive supportive care, which has proven effective when administered early. Researchers continue efforts to enroll the remaining target of nearly 1,000 participants to determine if the antiviral can effectively break the chain of transmission.
Frequently Asked Questions
Which specific strain of Ebola is the obeldesivir trial targeting?
The trial targets the Bundibugyo virus, which drives the current fast-moving outbreak in the Democratic Republic of the Congo and currently lacks an approved vaccine or treatment.
How many participants are required for the study, and who is eligible?
The study aims to recruit nearly 1,000 adults and children over the age of 12 who have had direct contact with a confirmed Ebola case within the last five days and are currently symptom-free.
What is the monitoring schedule for trial participants?
Participants are monitored in person every day for a duration of 21 days, followed by a final follow-up phone call at 42 days.
Which organizations are coordinating and supporting the trial?
The trial is coordinated by the medical non-profit Alima, in partnership with Congo’s National Institute of Biomedical Research and the French institute ANRS Emerging Infectious Diseases.
Related reading